Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.69 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.58 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.52 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4414111 | 0.81 | PRKCI (0.65) | PRKCICYP2A6CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL12903062 | 0.81 | CYP2A6 (0.55) | PRKCICYP2A6CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL4415545 | 0.81 | PRKCI (0.65) | PRKCICYP2A6CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL3607664 | 0.81 | CYP2A6 (1.00) | PRKCICYP2A6CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL20881276 | 0.81 | PRKCI (0.55) | PRKCICYP2A6CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL10084289 | 0.78 | CYP2A6 (0.64) | PRKCICYP2A6CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL25078434 | 0.77 | LTA4H (0.58) | PRKCICYP2A6CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL13078022 | 0.76 | HTT (0.55) | PRKCICYP2A6CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL5972875 | 0.76 | CYP2A6 (0.62) | PRKCICYP2A6CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL24040189 | 0.74 | CYP2A6 (0.60) | PRKCICYP2A6CYP2C9CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9486497-B2 | Treatment of immunocompromised conditions | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-11-08 | — | — | US | disclosed |
| US-9486497-B2 | Treatment of immunocompromised conditions | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-11-08 | — | — | US | disclosed |
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-07-07 | — | — | US | disclosed |
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-07-07 | — | — | US | disclosed |
| US-9254322-B2 | Compositions comprising E-selectin antagonists and uses therefor | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-02-09 | — | — | US | disclosed |
| EP-2915539-A1 | Treatment of immunocompromised conditions with E-Selectin antagonist and G-CSF | Mater Medical Research Institute (AU) | 2015-09-09 | — | — | EP | disclosed |
| US-8022076-B2 | Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents | XENTION LIMITED (GB) | 2011-09-20 | — | — | US | disclosed |
| US-20110020270-A1 | TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE | 2011-01-27 | — | — | US | disclosed |
| US-20110002881-A1 | TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE (AU) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020270-A1 | TREATMENT AND PROPHYLAXIS | SELP, SELE, SELL | PRKCI 1443/4885CYP2A6 4239/4885CYP2C9 4512/4885 |
| US-20110002881-A1 | TREATMENT AND PROPHYLAXIS | SELP, SELE, SELPLG | PRKCI 2602/4885CYP2A6 3976/4885CYP2C9 3820/4885 |
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | SELL, SELP, SELE | PRKCI 2379/4885CYP2A6 4138/4885CYP2C9 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.